VIVS

VivoSim Labs, Inc. (VIVS) - 10-Q Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended December 31, 2025 (Fiscal Q3 2026). VivoSim Labs, Inc. (formerly Organovo Holdings, Inc.) is a pharmaceutical and biotechnology services company focused on providing drug testing using 3D human tissue models of the liver and intestine. In March 2025, the Company sold its FXR314 drug program for $10.0 million and rebranded to reflect a shift toward a services-based model utilizing its New Approach Methodologies (NAM) for toxicology screening.

Key Financial Metrics

Note: All figures in thousands except per share data. Revenue consists primarily of royalty revenue from a license agreement with BICO Group AB.

Material Changes vs. Prior Period

• Revenue: Total revenue for the three months ended Dec 31, 2025, increased to $26,000 from $24,000 in the prior year period, driven by a 73% increase in royalty revenue. Product revenue was $0, down from $9,000, as the Mosaic product division ceased operations.
• Expenses: Research and Development (R&D) expenses decreased 36% to $1.14 million (from $1.78 million) due to reduced headcount (10 vs. 13 employees) and lower material costs. Selling, General, and Administrative (SG&A) expenses decreased 4% to $1.64 million.
• Liquidity: Cash and cash equivalents decreased from $11.3 million at March 31, 2025, to $4.3 million at December 31, 2025. Net cash used in operating activities was $8.6 million for the nine-month period.
• Capital Structure: The Company issued 701,729 shares of common stock via its At-The-Market (ATM) facility during the nine months ended Dec 31, 2025, raising net proceeds of approximately $1.8 million.

Outlook, Risks, and Management Commentary

• Going Concern: Management has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern for at least one year following the issuance date. The Company requires substantial additional funding to support operations and has an accumulated deficit of $350.2 million.
• Strategic Focus: The Company is pivoting to a services model, offering liver and intestinal toxicology insights. It aims to have a product candidate for its Preclinical IBD Program ready for an Investigational New Drug (IND) application by December 2026.
• Legal Contingencies: The Company is involved in litigation with H.C. Wainwright & Co., LLC regarding a tail financing provision. An accrual of $0.6 million has been recorded for this loss contingency.
• Financing Constraints: Due to a public float of less than $75 million, the Company is limited to raising one-third of its public float in any 12-month period via shelf registration statements. As of Dec 31, 2025, approximately $3.1 million remains available under the ATM program.
• Nasdaq Compliance: The Company is subject to a Mandatory Panel Monitor until April 30, 2026, due to prior non-compliance with the minimum stockholders' equity requirement ($2.5 million). Failure to regain compliance could result in delisting.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $4.3 million cash balance against the projected $10–$12 million operating expense for the fiscal year ending March 31, 2026.
• Financing Availability: Assess the likelihood of securing additional capital given the "substantial doubt" going concern warning and the $75 million public float restriction on ATM offerings.
• Revenue Sustainability: Confirm the stability of royalty revenue from the BICO Group AB license, which currently represents the entirety of the Company's revenue stream.
• Legal Exposure: Monitor the status of the H.C. Wainwright litigation and the potential for the $0.6 million accrual to increase.
• Nasdaq Status: Track compliance with Nasdaq listing rules, specifically the minimum stockholders' equity requirement, to avoid delisting.